Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old~2. NK stage 2 or 3 (Mackie classification)~3. Signed Informed Consent Form~4. The patient is able to understand the nature of the study and to participate throughout its duration~Exclusion Criteria:~1. Medical history of eye tumors~2. Active eye infection~3. Eyelid bad position or eyelid closure problems~4. Conjunctiva scarring~5. Topic chronic eye treatments with corticoids~6. Acute corneal burns (\<3 months)~7. Intolerance to contact lens~8. Allergy or inability to receive concomitant treatment with Exocin®~9. Patients with immunosuppressive or chemotherapy treatment~10. Pregnant woman or woman without proper contraceptive methods according to the investigator (\*), or lactating women~11. Participation in another clinical trial in the last month (\*) Contraceptive methods accepted in the protocol are: hormonal, intrauterine device (IUD), barrier methods, voluntary sterilization or the patient has menopause \>1 year duration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cord blood eye drops (Type: EXPERIMENTAL): Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
- Conventional treatment (Type: ACTIVE_COMPARATOR): Conventional treatment:~1. Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic~2. Therapeutic Contact lens Description: Air Optix Night\&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular

Based on this trial design, predict the completion outcome and termination type (if applicable).